>>

>>

抑制剂/激活剂

>>

凋亡与自噬

>>

Gemcitabine 吉西他滨; LY 188011

Gemcitabine (LY 188011) 是一种嘧啶核苷类似物抗代谢药 (nucleoside antimetabolite/analog) 和抗肿瘤剂。Gemcitabine 抑制 DNA 合成 (DNA synthesis) 和修复，导致细胞自噬 (autophagy) 和凋亡 (apoptosis)。

货号：
TK0249
规格：

5mg

10mg

25mg

100mg

200mg
价格：
￥0.00

产品参数

CAS No.	95058-81-4
生物活性	Gemcitabine (LY 188011) is a pyrimidine nucleoside analog antimetabolite and an antineoplastic agent. Gemcitabine inhibits DNA synthesis and repair, resulting in autophagyand apoptosis.
分子式	C9H11F2N3O4
分子量	263.20
运输条件	Room temperature in continental US; may vary elsewhere.
储存条件	4°C, protect from light
溶解性数据	DMSO : 250 mg/mL (949.85 mM; Need ultrasonic) Ethanol : 12.5 mg/mL (47.49 mM; Need ultrasonic)
体内研究	Gemcitabine can be administered via endotracheal spray in rats without marked toxicity with a maximum tolerated dose of 4 mg/kg once a week for 9 weeks. The toxicity of Gemcitabine is lower via lung than oral administration at dosages of 2, 4, and 6 mg/kg. Treatment of the LSL-Kras; LSL-Trp53; Pdx-1-Cre mice with either Gemcitabine (50 mg/kg, i.p.) or the combination DMAPT/Gemcitabine significantly increases the median survival time by more than 30 days compared to the placebo group (254.5 or 255 days vs. 217.5 days, respectively).
体外研究	Gemcitabine (purchased from MedChem Express, 0.003-1 μM; 3 days) kills both mouse and human senescent cells effectively and potently. Gemcitabine inhibits the growth of BxPC-3, Mia Paca-2, PANC-1, PL-45 and AsPC-1 cells with IC50s of 37.6, 42.9, 92.7, 89.3 and 131.4 nM, respectively.
文献	•Nature. 2019 Oct;574(7777):264-267. •Adv Mater. 2021 May;33(18):e2100949. •Cell Res. 2020 Jul;30(7):574-589. •Gastroenterology. 2021 Nov;161(5):1601-1614.e23. •Sci Transl Med. 2021 Jan 20;13(577):eaba7401. •Hepatology. 2019 May;69(5):1995-2012. •Redox Biol. 2021 Jan;38:101807. •Theranostics. 2021 Mar 24;11(12):5650-5674. •J Exp Clin Cancer Res. 2021 Nov 25;40(1):373. •Cell Mol Life Sci. 2021 Oct 13. •Br J Pharmacol. 2021 Jun;178(12):2496-2515. •Cell Prolif. 2021 Apr 1;e13038. •Int J Biol Sci. 2022; 18(1):43-64. •Int J Biol Sci. 2021 Oct. •Biomed Pharmacother. 2019 Sep;117:109185. •Front Oncol. 2021 Jul 13;11:704042. •Am J Cancer Res. 2020 Nov 1;10(11):3896-3910. •Am J Cancer Res. 2020 Apr 1;10(4):1182-1193. •Biochem Pharmacol. 2021 Oct 18;193:114813. •Biochem Pharmacol. 2020 Jun 6;114085. •Aging. 2020 Aug 28;12(16):16304-16325. •Cell Death Discov. 2021 May 1;7(1):89. •Chem Biol Interact. 2018 Jun 25;290:44-51. •J Biol Chem. 2017 Jun 2;292(22):9136-9149. •Mol Pharm. 2021 Jun 2. •Chinese Chemical Letters. •Cancer Med. 2019 Oct;8(13):5903-5915. •J Mol Med (Berl). 2019 Aug;97(8):1183-1193. •Mol Immunol. 2019 May;109:140-148. •Transl Oncol. 2020 Sep;13(9):100804. •Onco Targets Ther. 2020 Sep 28;13:9543-9558. •Onco Targets Ther. 2019 Jun 12;12:4585-4593. •J Pharmacol Exp Ther. 2018 Oct;367(1):20-27. •Oncol Rep. 2022 Feb;47(2):33. •Exp Cell Res. 2020 Dec 1;397(1):112335. •PLoS Negl Trop Dis. 2019 Aug 20;13(8):e0007681. •Invest New Drugs. 2022 Jan 4. •Acta Biochim Biophys Sin. 2021 Jan 12;gmaa177. •Int J Med Sci. 2022; 19(2): 286-298. •Int J Med Sci. 2022 Jan. •Biomed J. 2020 Aug;43(4):368-374. •Urol Oncol. 2021 Mar;39(3):194.e1-194.e7. •DNA Cell Biol. 2021 Dec 13. •Eur Rev Med Pharmacol Sci. 2019 Jan;23(2):649-659. •Oncol Lett. June 30, 2021. •SLAS Discov. 2018 Aug;23(7):687-696. •Biol Pharm Bull. 2021 Dec 22. •Naunyn Schmiedebergs Arch Pharmacol. 2019 May;392(5):615-622. •Int J Clin Exp Pathol. 2017;10(3):3033-3042. •Research Square Preprint. 2021 Nov. •Patent. US20210260092A1. •Research Square Preprint. 2021 Aug. •ÁREA DE FARMACIA Y TECNOLOGÍA FARMACÉUTICA. DEPARTAMENTO DE INGENIERÍA. 2020 Oct. •Oncotarget. 2017 Oct 6;8(52):90185-90196. •Chinese Pharmacological Bulletin. 2017, 33(6): 788-792.
纯度及产品资料	98%

推荐产品